HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulation/Legislation (Health)

Set Alert for Regulation {Health}

Regulation

Set Alert for Regulation {Health}

Latest From Health & Regulation

Longer Exclusivity Periods For EU Centralized Rx-To-OTC Switches? Commission Says No

One way to revitalize interest in the EU's centralized switch procedure would be to introduce longer data exclusivity periods or market exclusivity for successful applicants, concluded an AESGP expert switch panel presenting at the association's 59th Annual Meeting in Paris, France. However, a European Commission representative told another panel that this was not under consideration as part of the EU pharmaceutical legislation revision.

Europe Health

Pending Decision On First US OTC Birth Control Shines Spotlight On Self-Report Study Data

Approval likely would account for all weight on scale of FDA decision if not for self-report element in design of HRA Pharma’s actual use study for OTC switch of 0.075-mg norgestrel branded Opill. HRA’s sNDA offers lesson for using electronic diary apps in self-report studies.

FDA Prescription To OTC Switch

AESGP Annual Meeting: OTC Antifungals, Antivirals Could Become Rx In EU

The European Commission shocked participants at this year's AESGP Annual Meeting by warning that OTC antifungals, like treatments for athlete’s foot, and OTC antivirals, like cold sore creams, could soon become prescription-only within the region, under proposed revisions to the EU pharma legislation. There is hope, however. The proposals are still open to feedback from industry, the AESGP points out, and even if this proposal becomes law, member states can waive this prescription requirement under certain conditions.

Europe Health
See All

Legislation

Set Alert for Legislation {Health}

Latest From Health & Legislation

Longer Exclusivity Periods For EU Centralized Rx-To-OTC Switches? Commission Says No

One way to revitalize interest in the EU's centralized switch procedure would be to introduce longer data exclusivity periods or market exclusivity for successful applicants, concluded an AESGP expert switch panel presenting at the association's 59th Annual Meeting in Paris, France. However, a European Commission representative told another panel that this was not under consideration as part of the EU pharmaceutical legislation revision.

Europe Health

What Would US FDA Do If Supreme Court Eliminates Or Curtails Chevron Deference?

Lawyers say agency will have to bolster its administrative record as judges tackle complex policy and scientific issues previously left to FDA. Some cases, such as challenges to exclusivity decisions, may be reopened.

Politics Legal Issues

House Appropriations Subcommittee Proposes FDA FY2024 Budget $662M Short Of Request

Appropriations Agriculture, Rural Development, FDA and Related Agencies Subcommittee marked up its FY2024 bill on 18 May, proposing $6.579bn for FDA. Total is up from current budget of $6.562bn, but Biden administration proposed $7.2bn for FY2024.

FDA Consumer
See All
UsernamePublicRestriction

Register